Item Type | Name |
Academic Article
|
9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice.
|
Academic Article
|
Alpha 4 integrin increases anoikis of human osteosarcoma cells.
|
Academic Article
|
Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.
|
Academic Article
|
Anti-cancer activity of 9-nitrocamptothecin liposome aerosol in mice.
|
Concept
|
Osteosarcoma
|
Academic Article
|
Metastatic epidural osteosarcoma initially diagnosed as cisplatin neuropathy.
|
Academic Article
|
Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
|
Academic Article
|
Osterix, a transcription factor for osteoblast differentiation, mediates antitumor activity in murine osteosarcoma.
|
Academic Article
|
Association of alphavbeta3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells.
|
Academic Article
|
Fas expression in lung metastasis from osteosarcoma patients.
|
Academic Article
|
Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases.
|
Academic Article
|
Fas expression in metastatic osteosarcoma cells is not regulated by CpG island methylation.
|
Academic Article
|
Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases.
|
Academic Article
|
Expression of c-FLIP in pulmonary metastases in osteosarcoma patients and human xenografts.
|
Academic Article
|
Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis.
|
Academic Article
|
Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis.
|
Academic Article
|
Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
|
Academic Article
|
Liposomal MTP-PE.
|
Academic Article
|
Osteosarcoma metastatic to the pancreas in young patients.
|
Academic Article
|
Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma.
|
Academic Article
|
Interferon-alpha enhances the sensitivity of human osteosarcoma cells to etoposide.
|
Academic Article
|
ImmTher, a lipophilic disaccharide derivative of muramyl dipeptide, up-regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activity.
|
Academic Article
|
Biologic response modifiers in pediatric cancer.
|
Academic Article
|
Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector.
|
Academic Article
|
Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases.
|
Academic Article
|
Interleukin-12 enhances the sensitivity of human osteosarcoma cells to 4-hydroperoxycyclophosphamide by a mechanism involving the Fas/Fas-ligand pathway.
|
Academic Article
|
Increased Fas expression reduces the metastatic potential of human osteosarcoma cells.
|
Academic Article
|
Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients.
|
Academic Article
|
Intravenous administration of the conditionally replicative adenovirus Ad5-Delta24RGD induces regression of osteosarcoma lung metastases.
|
Academic Article
|
The osterix transcription factor down-regulates interleukin-1 alpha expression in mouse osteosarcoma cells.
|
Academic Article
|
Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.
|
Academic Article
|
Inhibition of Cdc42-interacting protein 4 (CIP4) impairs osteosarcoma tumor progression.
|
Academic Article
|
Knockdown of autophagy-related protein 5, ATG5, decreases oxidative stress and has an opposing effect on camptothecin-induced cytotoxicity in osteosarcoma cells.
|
Academic Article
|
Osteosarcoma: the state of affairs dictates a change. What do we know?
|
Academic Article
|
Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid).
|
Academic Article
|
Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
|
Academic Article
|
Antitumor activity of TNF-alpha, IL-1, and IFN-gamma against three human osteosarcoma cell lines.
|
Academic Article
|
Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma.
|
Academic Article
|
Liposomal MTP-PE for the adjuvant therapy of osteosarcoma.
|
Academic Article
|
Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
|
Academic Article
|
Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy.
|
Academic Article
|
A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies.
|
Academic Article
|
Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells.
|
Academic Article
|
Eradication of osteosarcoma lung metastasis using intranasal gemcitabine.
|
Academic Article
|
Interleukin-1 alpha increases the cytotoxic activity of etoposide against human osteosarcoma cells.
|
Academic Article
|
Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.
|
Academic Article
|
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
|
Academic Article
|
Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases.
|
Academic Article
|
Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine.
|
Academic Article
|
Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma.
|
Academic Article
|
VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells.
|
Academic Article
|
Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.
|
Academic Article
|
Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs.
|
Academic Article
|
The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases.
|
Academic Article
|
Epigenetic regulation of apoptosis and cell cycle in osteosarcoma.
|
Academic Article
|
Genetically modified T cells targeting interleukin-11 receptor a-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases.
|
Academic Article
|
miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression.
|
Academic Article
|
MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts.
|
Academic Article
|
The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases.
|
Academic Article
|
Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases.
|
Academic Article
|
In vitro and in vivo effect of adriamycin therapy on monocyte activation by liposome-encapsulated immunomodulators.
|
Academic Article
|
Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
|
Academic Article
|
Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases.
|
Academic Article
|
COX-2 expression correlates with survival in patients with osteosarcoma lung metastases.
|
Academic Article
|
Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs.
|
Academic Article
|
Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity.
|
Academic Article
|
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
|
Academic Article
|
Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group.
|
Academic Article
|
Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines.
|
Academic Article
|
Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.
|
Academic Article
|
Toward a drug development path that targets metastatic progression in osteosarcoma.
|
Academic Article
|
Osteosarcoma metastatic to the pancreas in young patients
|
Academic Article
|
Mifamurtide in metastatic and recurrent osteosarcoma
|
Academic Article
|
Current advances in osteosarcoma
|
Academic Article
|
Current advances in osteosarcoma[Advances in Experimental Medicine and Biology, DOI 10.1007/978-3-319-04843-7_20]
|
Academic Article
|
Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of osteosarcoma
|
Academic Article
|
Maximum benefit of chemotherapy for osteosarcoma achieved-what are the next steps?
|
Academic Article
|
Hes4: A potential prognostic biomarker for newly diagnosed patients with high-grade osteosarcoma.
|
Academic Article
|
Osteosarcoma Overview.
|
Academic Article
|
Effect of entinostat on NK cell-mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis.
|
Academic Article
|
miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating FAS Promoter Activity and Can be Therapeutically Targeted to Inhibit Lung Metastases.
|
Academic Article
|
Analysis of HSP27 and the Autophagy Marker LC3B+ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients.
|
Academic Article
|
Aerosol Gemcitabine after Amputation Inhibits Osteosarcoma Lung Metastases but Not Wound Healing.
|
Academic Article
|
Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases.
|
Academic Article
|
Phosphorylated heat shock protein 27 as a potential biomarker to predict the role of chemotherapy-induced autophagy in osteosarcoma response to therapy.
|
Academic Article
|
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial.
|
Academic Article
|
Using the Spleen as an In Vivo Systemic Immune Barometer Alongside Osteosarcoma Disease Progression and Immunotherapy with a-PD-L1.
|
Academic Article
|
Short-Term Changes in Cardiac Function in Osteosarcoma Patients Receiving Anthracyclines.
|
Academic Article
|
BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation.
|
Academic Article
|
Knock down of Fas-Associated Protein with Death Domain (FADD) Sensitizes Osteosarcoma to TNFa-induced Cell Death.
|
Academic Article
|
Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+ conventional dendritic cells.
|
Academic Article
|
Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions.
|
Academic Article
|
Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention.
|
Academic Article
|
The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases.
|
Academic Article
|
Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma.
|
Academic Article
|
Up-regulation of pro-angiogenic molecules and events does not relate with an angiogenic switch in metastatic osteosarcoma cells but to cell survival features.
|
Academic Article
|
Exercise intervention decreases acute and late doxorubicin-induced cardiotoxicity.
|
Academic Article
|
Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming.
|